At a glance
ClinicalIndex Comparison RecordN/ACompleted· 756 enrolled
Drug / intervention
bimatoprost/timololdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Safety and Efficacy of Bimatoprost/Timolol (Ganfort®) Ophthalmic Solution in Korea
In Brief
An observational study evaluating bimatoprost/timolol for Glaucoma, Open-Angle and Ocular Hypertension. Completed, enrolled 756 participants across 1 site.
Detailed Summary
This study is a Post-Marketing Surveillance study to evaluate the safety and efficacy of bimatoprost/timolol (Ganfort®) Ophthalmic Solution to treat open-angle glaucoma or ocular hypertension in Korea.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Open-Angle, Ocular Hypertension
CountriesSouth Korea
Collaborators--
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartAug 2009
First PostedNov 2013
Primary CompletionJan 2014
TodayJul 2026
First PostedNov 6, 2013
Enrollment StartAug 1, 2009
Primary CompletionJan 1, 2014
TodayJul 2, 2026
Enrollment to primary: 4.4 yearsPosted 12.7 years ago
Interventions
bimatoprost/timololdrug
Bimatoprost/timolol (Ganfort®) treatment for open-angle glaucoma or ocular hypertension as per local standard of care in clinical practice.